Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2021 Oct 18;1(3):oeab028.
doi: 10.1093/ehjopen/oeab028. eCollection 2021 Nov.

Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry

Abi Selvarajah  1 , Annerieke H Tavenier  1 , Wilbert L Bor  2 , Vital Houben  3 , Saman Rasoul  3   4 , Eliza Kaplan  5 , Koen Teeuwen  6 , Sjoerd H Hofma  7 , Erik Lipsic  8 , Giovanni Amoroso  9 , Maarten A H van Leeuwen  1 , Jur M Ten Berg  2   10 , Arnoud W J van 't Hof  1   3   4   10 , Renicus S Hermanides  1
Affiliations

Feasibility and safety of cangrelor in patients with suboptimal P2Y12 inhibition undergoing percutaneous coronary intervention: the Dutch Cangrelor registry

Abi Selvarajah et al. Eur Heart J Open. .
No abstract available

Keywords: Cangrelor; P2Y12 inhibitors; Percutaneous coronary intervention; Platelet inhibition.

PubMed Disclaimer

References

    1. Valgimigli M, Bueno H, Byrne RA, Collet J-P, Costa F, Jeppsson A, Jüni P, Kastrati A, Kolh P, Mauri L, Montalescot G, Neumann F-J, Petricevic M, Roffi M, Gabriel Steg P, Windecker S, Zamorano JL.. 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: The Task Force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart 2017;39:213–260. - PubMed
    1. Alexopoulos D, Xanthopoulou I, Gkizas V, Kassimis G, Theodoropoulos KC, Makris G, Koutsogiannis N, Damelou A, Tsigkas G, Davlouros P, Hahalis G.. Randomized assessment of ticagrelor versus prasugrel antiplatelet effects in patients with ST-segment-elevation myocardial infarction. Circ Cardiovasc Interv 2012;5:797–804. - PubMed
    1. Steg PG, Bhatt DL, Hamm CW, Stone GW, Gibson CM, Mahaffey KW, Leonardi S, Liu T, Skerjanec S, Day JR, Iwaoka RS, Stuckey TD, Gogia HS, Gruberg L, French WJ, White HD, Harrington RA.. Effect of cangrelor on periprocedural outcomes in percutaneous coronary interventions: a pooled analysis of patient-level data. Lancet 2013;382:1981–1992. - PubMed
    1. Selvarajah A, Tavenier AH, Bor WL, Houben V, Rasoul S, Kaplan E, Teeuwen K, Hofma SH, Lipsic E, Amoroso G, van Leeuwen MAH, Berg J. M T, van ‘T Hof AWJ, Hermanides RS.. Feasibility and safety of cangrelor in patients with suboptimal P2Y(12) inhibition undergoing percutaneous coronary intervention: rationale of the Dutch Cangrelor Registry. BMC Cardiovasc Disord 2021;21:292. - PMC - PubMed